***We no longer follow the companies mentioned in these backdated newsletter issues. These samples of past newsletters are generated to give you an idea of what you can expect when you subscribe. Please do not use any of the information contained in the samples below as current advice. If you would like to purchase a newsletter subscription, please click here. ***

Hello Readers,

Since the last Newsletter, we closed one position.

MEDICINOVA (5/20/11). Closed position 5/11/12 at $3.90 for a 58% GAIN.

MediciNova’s stock got a pretty nice pop on an upbeat earnings report about its various product candidates. Since this is our first gain in nearly seven weeks, due to the market slide, we see it as a small victory rather than a reason to do cartwheels.

(more…)

***We no longer follow the companies mentioned in these backdated newsletter issues. These samples of past newsletters are generated to give you an idea of what you can expect when you subscribe. Please do not use any of the information contained in the samples below as current advice. If you would like to purchase a newsletter subscription, please click here. ***

Hello Readers,

“Sell in May and go away”, the old market adage goes. The trouble is that the May selling started in early April, and, as we pen this copy, it doesn’t seem likely to stop anytime, soon. There are, of course, the usual bugaboos that we have harped upon over the last few Newsletters, especially the uneasiness in Europe. However, we think that traders are beginning to realize that the recovery isn’t much of a recovery at all, and this has been spooking them. Also, all of the “good” earnings news may not have been all of that great when one considers that most expectations were on the low side, making numbers easy to beat. However, here is the “real” good news, which, to us, is a sad commentary. If the markets drop a thousand or so points, the Fed will probably rush in with added liquidity. As we have periodically said, welcome to the new age of market socialism.

(more…)

***We no longer follow the companies mentioned in these backdated newsletter issues. These samples of past newsletters are generated to give you an idea of what you can expect when you subscribe. Please do not use any of the information contained in the samples below as current advice. If you would like to purchase a newsletter subscription, please click here. ***

Hello Readers,

You can sum up the market action of the last few weeks in one word: UGLY. What surprised us is that Fed Chairman Ben did not run to a microphone announcing that he was going to throw more money around. Actually, he sent a few of his top board members to do the work for him, sort of. When the markets appeared ready for a healthy correction, Fed Vice Chairman Yellon announced that the Fed was ready to act if there were signs of economic weakness. That seemed to calm things, for a few days. Hey, there’s nothing like market socialism, right? And, once again, we must remind you that when these sort of gut-wrenching selloffs occur, small stocks get pounded even worse than the big and mid-caps. So, it is no small surprise that our Current Portfolio was bruised pretty badly. And, for what is probably the first time this year, we did close any new positions since the last Newsletter, which can be mostly blamed on the recent market drop.

(more…)

***We no longer follow the companies mentioned in these backdated newsletter issues. These samples of past newsletters are generated to give you an idea of what you can expect when you subscribe. Please do not use any of the information contained in the samples below as current advice. If you would like to purchase a newsletter subscription, please click here. ***

Hello Readers,

Since the last Newsletter, we have closed five more positions; two for gains and three for losses.

OREXIGEN THERAPEUTICS (2/20/12). Closed position 3/19/12 at $5.12 for a 68% GAIN.

CERUS CORP. (3/20/10). Closed position 3/20/12 at $4.50 for a 60% GAIN.

OPNEXT (6/20/11). Closed position 3/26/12 at $1.73 for a 19% LOSS.

XATA CORP. (9/20/07). Closed position 3/20/12 at $1.33 for a 56% LOSS.

World Heart (11/20/10). Closed position 3/30/12 at 29 cents for a 89% LOSS.

(more…)

***We no longer follow the companies mentioned in these backdated newsletter issues. These samples of past newsletters are generated to give you an idea of what you can expect when you subscribe. Please do not use any of the information contained in the samples below as current advice. If you would like to purchase a newsletter subscription, please click here. ***

Hello Readers,

Since the last Newsletter, we closed four positions; three for gains and one for a loss.

VERMILLION (12/5/11). Closed position 3/6/12 at $2.95 for a 122% GAIN.

GALENA BIOPHARMA (7/5/11). Closed position 3/5/12 at $1.70 for a 70% GAIN.

KERYX BIOPHARMACEUTICALS (10/5/11). Closed position 3/5/12 at $5.00 for a 67% GAIN.

TRIDENT MICROSYSTEMS (12/20/10). Closed position 3/5/12 at 35 cents for an 89% LOSS.

(more…)

***We no longer follow the companies mentioned in these backdated newsletter issues. These samples of past newsletters are generated to give you an idea of what you can expect when you subscribe. Please do not use any of the information contained in the samples below as current advice. If you would like to purchase a newsletter subscription, please click here. ***

Hello Readers,

Since the last Newsletter, we closed two positions; one for a gain and one for a loss.

CORCEPT THERAPEUTICS (10/5/11). Closed position 2/21/12 at $4.86 for a 65% GAIN.

MICROVISION (5/20/08). Closed position 2/29/12 at $3.34 for an 88% LOSS.

(more…)

***We no longer follow the companies mentioned in these backdated newsletter issues. These samples of past newsletters are generated to give you an idea of what you can expect when you subscribe. Please do not use any of the information contained in the samples below as current advice. If you would like to purchase a newsletter subscription, please click here. ***

Hello Readers,

Since the last Newsletter, we closed seven positions; five for gains and two for losses.

BioCryst Biopharmaceuticals (10/20/11). Closed position 2/15/12 at $4.26 for a 55% GAIN.

DRY SHIPS (12/20/11). Closed position 2/14/12 at $3.78 for a 77% GAIN.

NUPATHE (12/20/11). Closed position 2/9/12 at $3.42 for a 74% GAIN.

SMITH MICRO SOFTWARE (2/5/12). Closed position 2/8/12 at $2.83 for a 56% GAIN.

GLU MOBILE (9/5/11). Closed position 2/9/12 at $4.65 for a 52% GAIN

BLUE PHOENIX (10/20/10). Closed position 2/6/12 at $2.67 for a 70% LOSS.

(more…)

***We no longer follow the companies mentioned in these backdated newsletter issues. These samples of past newsletters are generated to give you an idea of what you can expect when you subscribe. Please do not use any of the information contained in the samples below as current advice. If you would like to purchase a newsletter subscription, please click here. ***

Hello Readers,

Since the last Newsletter, we closed four positions, three for gains and one for a loss.

NAUTILUS (8/20/11). Closed position 1/30/12 at $2.53 for a 51% GAIN.

CELLDEX THERAPEUTICS (9/20/11). Closed position 1/27/12 at $4.53 for a 68% GAIN.

TRANS1 (1/5/12). Closed position 1/27/12 at $2.93 for a 57% GAIN.

APPLIED ENERGETICS (7/5/08). Closed position 1/25/12 at 10 cents for a 94% LOSS.

Nautilus got a very nice lift due to a strong earnings forecast. Several news items about various clinical trials, along with a brokerage house upgrade, sent shares of Celldex Therapeutics on a nice run. We have no clue as to what made TranS1 pierce our 50%-plus threshold, but, considering it was in the Current Portfolio for less than a month, we’ll take it. And, we finally closed Applied Energetics for a nasty loss.

(more…)

***We no longer follow the companies mentioned in these backdated newsletter issues. These samples of past newsletters are generated to give you an idea of what you can expect when you subscribe. Please do not use any of the information contained in the samples below as current advice. If you would like to purchase a newsletter subscription, please click here. ***

Hello Readers,

Since the last Newsletter, we closed one position for a gain.

BIODELIVERY SCIENCES (11/5/11). Closed position 1/6/12 at $1.93 for a 105% GAIN.

It was a great way to begin 2012 when BioDelivery Sciences inked a licensing deal with Endo Pharmaceuticals for BDSI’s BEMA Buprenophrine, which sent the stock into a nosebleed. Now, here’s something that happens to us about once a decade. Last April, 2011, we closed previous pick Inhibitex at $4.78 for a 103% gain and thought that was pretty nifty, which it was. This past January 10, the company was acquired by BristolMyersSquibb for over $24 a share, which would have been a 925% gain. It’s fun to dream about the “if only”.

(more…)

***We no longer follow the companies mentioned in these backdated newsletter issues. These samples of past newsletters are generated to give you an idea of what you can expect when you subscribe. Please do not use any of the information contained in the samples below as current advice. If you would like to purchase a newsletter subscription, please click here. ***

HAPPY NEW YEAR READERS! (We hope)

Since the last Newsletter, we closed another position, for a gain.

FSI INTERNATIONAL (11/20/11). Closed position 12/28/11 at $3.74 for a 54%GAIN.

Even though FSI International missed on revenue expectations, the company did guide higher for the next quarter, which added even more juice to the stock that has performed well almost from the day we picked it. And, with the closing of FSI, we have now closed our 700^thposition since we began publishing in 1996. For the year 2011, we closed 46 positions, 31 were for gains and 15 were for losses, if we counted right.

(more…)